《2024年亚太肝病学会推荐意见:非肝硬化门静脉纤维化/特发性门静脉高压的诊断和管理》摘译  

An excerpt of non‑cirrhotic portal fibrosis/idiopathic portal hypertension:APASL recommendations for diagnosis and management(2024)

作　　者：夏俊琪 吕哲 刘成海 祁兴顺 XIA Junqi;LYU Zhe;LIU Chenghai;QI Xingshun(Department of Gastroenterology,General Hospital of Northern Theater Command,Shenyang 110840,China;PostgraduateCollege,China Medical University,Shenyang 110122,China;Institute of Liver Diseases,Shuguang Hospital Affiliated toShanghai University of Traditional Chinese Medicine,Shanghai Key Laboratory of Traditional Chinese Clinical Medicine,KeyLaboratory of Liver and Kidney Diseases,Ministry of Education,Shanghai 201203,China)

机构地区：[1]北部战区总医院消化内科,沈阳110840 [2]中国医科大学研究生院,沈阳110122 [3]上海中医药大学附属曙光医院肝病研究所,上海市中医临床重点实验室,肝肾疾病病证教育部重点实验室,上海201203

出　　处：《临床肝胆病杂志》2025年第1期41-43,共3页Journal of Clinical Hepatology

基　　金：国家重点研发计划(2023YFC2507500);辽宁省优秀青年基金计划(2022-YQ-07);辽宁省应用基础研究计划(联合计划)(2022JH2/101500032)。

摘　　要：近期,亚太肝病学会发布了有关非肝硬化门静脉纤维化(NCPF)/特发性门静脉高压(IPH)诊断和管理的推荐意见。该指南主要围绕NCPF/IPH的定义、诊断、组织学特征、自然病史和管理等方面进行了系统阐述,旨在加强当前对NCPF/IPH相关问题的理解,并建立全球共识。本文对指南中的重要声明进行摘译。Recently,Asian Pacific Association for the Study of the Liver published the recommendations for the diagnosis and management of non-cirrhotic portal fibrosis(NCPF)/idiopathic portal hypertension(IPH).The guidelines mainly elaborate on the definition,diagnosis,histological features,natural history,and management of NCPF/IPH,in order to strengthen the understanding of NCPF/IPH-related issues and establish a global consensus.This article makes an excerpt of the key statements in the guidelines.

关 键 词：肝疾病 纤维化 高血压 门静脉 诊疗准则 

分 类 号：R575.2[医药卫生—消化系统]